IL1B and amyloidosis: The proposed criteria for approval of IL1 inhibitors in colchicine-resistant FMF are for patients with evidence of persistent proteinuria or biopsy-proven amyloidosis or in those suffering from more than one attack per month over a period of several months in association with objective signs of inflammation (such as an elevation of C-reactive protein levels during and between attacks).